Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Noreen c. Gleeson, Fiona Buggy, Brian L Sheppard & John Bonnar. (1994) The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstetricia et Gynecologica Scandinavica 73:3, pages 274-277.
Read now
Read now
T. Padró, C. M. Van Den Hoogen & J. J. Emeis. (1991) Plasmin inhibitory effect of rat tissues: Comparison with antiplasmin activity of plasma. Scandinavian Journal of Clinical and Laboratory Investigation 51:7, pages 599-603.
Read now
Read now
Articles from other publishers (27)
Gunilla H?yer?Hansen & Ida Katrine Lund. 2007.
65
102
.
Helle Pappot, Anders N. Pedersen, Nils Br?nner & Ib J. Christensen. (2006) The complex between urokinase (uPA) and its type-1 inhibitor (PAI-1) in pulmonary adenocarcinoma: Relation to prognosis. Lung Cancer 51:2, pages 193-200.
Crossref
Crossref
Charlotte Elberling Almasi, Gunilla Høyer-Hansen, Ib Jarle Christensen, Keld Danø & Helle Pappot. (2005) Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 48:3, pages 349-355.
Crossref
Crossref
Christer Borgfeldt, Pär‐Ola Bendahl, Barbro Gustavsson, Eva Långström, Mårten Fernö, Roger Willén, Seija Grenman & Bertil Casslén. (2003) High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer. International Journal of Cancer 107:4, pages 658-665.
Crossref
Crossref
A.N Pedersen, H.T Mouridsen, D.Y Tenney & N Br?nner. (2003) Immunoassays of urokinase (uPA) and its type-1 inhibitor (PAI-1) in detergent extracts of breast cancer tissue. European Journal of Cancer 39:7, pages 899-908.
Crossref
Crossref
T. Kooistra & J. J. Emeis. 2001. Fibrinolytics and Antifibrinolytics. Fibrinolytics and Antifibrinolytics
521
556
.
HELLE PAPPOT. (2011) The plasminogen activation system in lung cancer — with special reference to the prognostic role in “non‐small cell lung cancer”. APMIS 107:S92, pages 5-29.
Crossref
Crossref
F. Descotes, G. Ville, J.Y. Bobin, Y. Barbier & S. Saez. (1998) Tissue extraction procedures for investigation of urokinase plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in human breast carcinomas. Breast Cancer Research and Treatment 49:2, pages 135-143.
Crossref
Crossref
Helle Pappot, Birgit Guldhammer Skov, Charles Pyke & Jan Grøndahl-Hansen. (1997) Levels of plasminogen activator inhibitor type 1 and urokinase plasminogen activator receptor in non-small cell lung cancer as measured by quantitative ELISA and semiquantitative immunohistochemistry. Lung Cancer 17:2-3, pages 197-209.
Crossref
Crossref
Anders N Pedersen, Gunilla Høyer-Hansen, Nils Brünner, Gary M Clark, Birthe Larsen, Hans S Poulsen, Keld Danø & Ross W Stephens. (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. Journal of Immunological Methods 203:1, pages 55-65.
Crossref
Crossref
Th.J. Benraad, J. Geurts-moespot, J. Gr?ndahl-hansen, M. Schmitt, J.J.T.M. Heuvel, J.H. de Witte, J.A. Foekens, R.E. Leake, N. Br?nner & C.G.J. Sweep. (1996) Immunoassays (ELISA) of urokinase-type plasminogen activator (uPA): Report of an EORTC/BIOMED-1 Workshop. European Journal of Cancer 32:8, pages 1371-1381.
Crossref
Crossref
Shingo Takano, Yoshihiko Yoshii, Tadao Nose, Barry Landau & Steven Brem. 1996. Brain Tumor. Brain Tumor
119
125
.
E. R�nne, G. H�yer-Hansen, N. Br�nner, H. Pedersen, F. Rank, C. K. Osborne, G. M. Clark, K. Dan� & J. Gr�ndahl-Hansen. (1995) Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Research and Treatment 33:3, pages 199-207.
Crossref
Crossref
J.M.M. Gijtenbeek, J.J. Emeis, J.J.van der Sande & R.E. Lulf. (1994) Different types of plasminogen activator activity in human brain tumours: relation with peritumoral oedema?. Clinical Neurology and Neurosurgery 96:4, pages 305-309.
Crossref
Crossref
Noreen C. Gleeson. (1994) Cyclic changes in endometrial tissue plasminogen activator and plasminogen activator inhibitor type 1 in women with normal menstruation and essential menorrhagia. American Journal of Obstetrics and Gynecology 171:1, pages 178-183.
Crossref
Crossref
Jeffrey M. Reilly, Gregorio A. Sicard & Charles L. Lucore. (1994) Abnormal expression of plasminogen activators in aortic aneurysmal and occlusive disease. Journal of Vascular Surgery 19:5, pages 865-872.
Crossref
Crossref
N. Gleeson, M. Devitt, B. L. Sheppard & J. Bonnar. (2005) Endometrial fibrinolytic enzymes in women with normal menstruation and dysfunctional uterine bleeding. BJOG: An International Journal of Obstetrics & Gynaecology 100:8, pages 768-771.
Crossref
Crossref
C. Rosenquist, S. M. Thorpe, K. Dan� & J. Gr�ndahl-Hansen. (1993) Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue. Breast Cancer Research and Treatment 28:3, pages 223-229.
Crossref
Crossref
N. Gleeson, R. Gonsalves & J. Bonnar. (1992) The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer. Gynecologic Oncology 47:1, pages 58-61.
Crossref
Crossref
Yoshihiro Hasui, Kousuke Marutsuka, Junji Suzumiya, Shinichiro Kitada, Yukio Osada & Akinobu Sumiyoshi. (2006) The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer. International Journal of Cancer 50:6, pages 871-873.
Crossref
Crossref
N. GLEESON, R. GONSALVES, E. McGUINNESS & J. BONNAR. (1991) Plasminogen activators in endometrial adenocarcinoma. International Journal of Gynecological Cancer 1:5, pages 223-226.
Crossref
Crossref
P.H. Quax, C.M. van den Hoogen, J.H. Verheijen, T. Padro, R. Zeheb, T.D. Gelehrter, T.J. van Berkel, J. Kuiper & J.J. Emeis. (1990) Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo.. Journal of Biological Chemistry 265:26, pages 15560-15563.
Crossref
Crossref
Pamela J. Jensen, Michelle John & Janet Baird. (1990) Urokinase and tissue type plasminogen activators in human keratinocyte culture. Experimental Cell Research 187:1, pages 162-169.
Crossref
Crossref
Shashikumar R. Harvey, David D. Lawrence, Judith M. Madeja, Steven J. Abbey & Gabor Markus. (1988) Secretion of plasminogen activators by human colorectal and gastric tumor explants. Clinical & Experimental Metastasis 6:6, pages 431-450.
Crossref
Crossref
S.M. Camiolo, G. Markus & M.S. Piver. (1987) Plasminogen activator content of gynecological tumors and their metastases. Gynecologic Oncology 26:3, pages 364-373.
Crossref
Crossref
J. GRSOSNDAHL-HANSEN, L.S. NIELSEN, P. KRISTENSEN, V. GRSOSNDAHL-HANSEN, P.A. ANDREASEN & K. DANSOS. (1985) Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. British Journal of Dermatology 113:3, pages 257-263.
Crossref
Crossref
V. Kielberg, P.A. Andreasen, J. Grøndahl-Hansen, L.S. Nielsen, L. Skriver & K. Danø. (2001) Proenzyme to urokinase‐type plasminogen activator in the mouse in vivo. FEBS Letters 182:2, pages 441-445.
Crossref
Crossref